In this TEDx talk, Heffter board member Roland Griffiths speaks about his research on psilocybin and the mystical experience. Griffiths and his team at Johns Hopkins recruited 36 individuals with experience in spiritual or religious activities but no prior use of psychedelics. Although the primary...
Heffter researcher Matt Johnson and his colleagues at Johns Hopkins University have completed a study showing that psilocybin (aka “magic mushrooms”) is a useful treatment for heavy smokers who want to quit. According to Bloomberg.com writer Michelle Fay Cortez:Just two or three experiences with the hallucinogenic...
A recent article in Scientific American highlights the need to reform federal drug policy. In “Turn On, Tune In, Get Better: Psychedelic Drugs Hold Medical Promise,” writer Roni Jacobson describes how the FDA and DEA created a Catch-22 situation for scientists who study psychedelics. The...
An article in the UK newspaper The Independent profiles Dr. Robin Carhart-Harris, a researcher at the Centre for Neuropsychopharmacology at Imperial College. Writer Laurence Phelan interviews Carhart-Harris about the history and current status of psychedelic research as well as his work using fMRI scanning technology to...
An article on the news site Vox features an in-depth interview with Heffter board member Dr. Charles Grob. “The Case for Medical LSD, Mushrooms, and Ecstasy,” by German Lopez, surveys the history and current status of psychedelic research. Dr. Grob discusses the potential of psychedelic...
An article by Kai Kupferschmidt in Science magazine gives a comprehensive survey of current psychedelic research. “High Hopes” focuses on the work of Heffter board member Stephen Ross and includes quotes from board members Roland Griffiths and Franz Vollenweider.“Albert Hofmann, the Swiss chemist who discovered...
According to The Washington Post, new research at Imperial College London shows that subjects injected with the psychedelic drug psilocybin exhibit brain activity that resembles the dreaming state. The researchers found that psilocybin increases activity in parts of the brain associated with emotion, memory, and...
Heffter co-founder David Nichols has an “Editors Pick” article on reset.me, a new web site devoted to journalism on psychedelics and related topics. In “When Will Medicinal ‘Magic Mushrooms’ Be Legalized?” Dr. Nichols gives an overview of Heffter-sponsored research using psilocybin to treat addiction, anxiety,...
An article in the New York Times “Fashion and Style” section covers the current popularity of the psychedelic beverage ayahuasca. The article features quotes from Heffter board member Charles Grob.“‘It”s a fascinating compound with a great deal to be learned from its effects,’ said Dr....
A new study uses fMRI technology to distinguish the effects of MDMA (“Ecstasy”) and the classic psychedelic psilocybin on the networks within the brain. Researchers found that psilocybin produces unique changes in consciousness.The effects of psilocybin and MDMA on between-network resting state functional connectivity in...
